ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.89+0.08 (+2.10%)
Close on Nov 13, 2026Market cap $386.85MP/E –Yield –
ARS Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
ARS Pharmaceuticals's price to sales ratio was 3.4× on Nov 11, 2026, against 6.6× a year earlier. Over the last 2 years it ranged from 2.9× to 492.6×, with a median of 9.7×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.4× | −4.7 |
| 2025 | Dec 31, 2025 | 8.1× | −391.0 |
| 2024 | Dec 31, 2024 | 399.1× | −64.9 |
| 2023 | Apr 28, 2023 | 464.0× | – |
See a number that looks wrong?